Tag results:
atopic dermatitis
Dermal Cell News
Connect Biopharma Reports Positive Top-Line Results from the Global Phase II Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis
[Connect Biopharma Holdings Limited] Connect Biopharma Holdings Limited reported positive topline results from the global Phase II clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe atopic dermatitis.
Dermal Cell News
DESCRIBE-AD: A Novel Classification Framework for Atopic Dermatitis
[Journal of the American Academy of Dermatology] The authors propose a novel framework to assess atopic dermatitis (AD) based on literature review and clinical experience. Rather than placing focus on any single specific aspect of AD, DESCRIBE-AD allows for a comprehensive approach to the assessment and clinical management of AD.
Dermal Cell News
Oncostatin M Can Sensitize Sensory Neurons in Inflammatory Pruritus
[Science Translational Medicine] Researchers found that the cytokine oncostatin M was highly up-regulated in psoriasis, atopic dermatitis, and cutaneous T cell lymphoma, diseases associated with chronic itch.
Dermal Cell News
Tpl2 Contributes to IL-1β-Induced IL-8 Expression via ERK1/2 Activation in Canine Dermal Fibroblasts
[PLoS One] Investigators established a model for interleukin 1β (IL-1β)-induced dermatitis and investigated mitogen-activated protein kinase signaling pathways in IL-1β-induced interleukin 8 (IL-8) expression.
Dermal Cell News
Phototherapy for Atopic Eczema
[Cochrane Database of Systematic Reviews] Investigators assess the effects of phototherapy for treating atopic eczema, a treatment used when topical treatments, such as corticosteroids, are insufficient or poorly tolerated.
Dermal Cell News
ASLAN Pharmaceuticals Announces Scientific Collaboration with Dr. Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers
[ASLAN Pharmaceuticals] ASLAN Pharmaceuticals announced a collaboration with renowned inflammatory skin disease expert Dr. Emma Guttman-Yassky to conduct research that will continue throughout ASLAN’s Phase IIb program to identify and characterize the effects of ASLAN004 on disease-associated skin and serum-biomarkers in adults with moderate-to-severe atopic dermatitis.